<DOC>
	<DOCNO>NCT01703364</DOCNO>
	<brief_summary>This trial patient previously untreated CLL . Eligible patient receive Lenalidomide backbone Fludarabine Rituximab 6 therapy cycle . Lenalidomide increase dose step 5 mg every cycle absence limit toxicity . If limiting toxicity ensue patient treat last tolerable dose remainder 6 treatment cycle . The first 5 patient start dose level 5 mg Lenalidomide escalate dose . After fifth patient include study , enrolment interrupt patient finish first treatment cycle . A safety board evaluate toxicity first 5 patient . If 2 patient experience dose limit toxicity ( DLT ) first treatment cycle , start dose escalate 5 patient enrol start dose 5 mg Lenalidomide . If 2 less patient experience DLT first treatment cycle , next 5 patient start treatment 10 mg Lenalidomide . The rational high start dos stem lack tumor lysis tumor flare toxicity combination one hand observation slow escalation 2,5 mg lead lack efficacy monotherapy trial due early progression relevant number case . The increase Lenalidomide dosage result increase efficacy especially begin higher cumulative dose Lenalidomide . The identification patient intolerant Lenalidomide immunophenotyping T cell validation also part trial , intolerance seem dose dependent may cause T cell activation . Therefore , early identification patient intolerant form modern immunochemotherapy establish efficient Lenalidomide base combination therapy important part improvement current CLL treatment .</brief_summary>
	<brief_title>Fludarabine/Rituximab Combined With Escalating Doses Lenalidomide Untreated CLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Vidarabine Phosphate</mesh_term>
	<criteria>Signed write informed consent Male female ≥ 18 year age CLL ( determine CD23+ , CD5+ , CD19+ ) Treatment indication define NCI Workshop criterion ( see appendix 6 reference 10 ) ECOG ≤ 2 No previous treatment CLL chemotherapy , radiotherapy ( except localize radiotherapy 1 lymphatic area ) immunotherapy Life expectancy &gt; 6 month ( except prognosis due high risk CLL ) Active bacterial , viral fungal infection Positivity HIV , Hepatitis B C Patients known history thromboembolic event Reduced organ function bone marrow dysfunction due CLL Creatinine clearance 30 ml/min Patients know history thromboembolic event Patients history malignancy within 2 year prior study entry ( except adequately treat carcinoma situ cervix ; basal squamous cell skin cancer ; low grade , early stage localize prostate cancer treat surgically curative intent ; good prognosis DCIS breast treat lumpectomy alone curative intent ) Patients medical comorbid condition would require long term use ( &gt; 1 month ) systemic corticosteroid study treatment Patients history severe cardiac disease ; e.g . NYHA Functional Class III IV heart failure , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina Other know comorbidity potential dominate survival Transformation aggressive Bcell malignancy ( e.g. , large Bcell lymphoma , Richter 's syndrome , prolymphocytic leukemia ( PLL ) ) Hypersensitivity anaphylactic reaction humanise monoclonal antibody apply drug Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol Administration investigational agent ( ) within 4 week prior entry Pregnancy lactation Medical psychological condition opinion Investigator would permit patient complete study sign meaningful inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>AGMT</keyword>
	<keyword>T cell</keyword>
</DOC>